RSSL provides MHRA and FDA accredited GMP quality control (QC) analyses of pharmaceuticals, biopharmaceuticals and healthcare products. 

Pharmaceutical manufacturers and their suppliers face a heavy burden to meet quality standards required by international legislation.  Not every manufacturer has the resource available to test, nor the expertise or equipment to test and interpret results.

Whether applying the pharmacopoeia monographs, transferring in your own methods, or developing new methods on your behalf, we can provide GMP QC testing services for your APIs, excipients and drug products.

Our wide ranging chemical, physical, biopharmaceutical and microbiological services are all about supporting you through the development and manufacturing process, ensuring your product’s integrity from raw material to market.

We can also detect impurities in the production of raw materials that contain amino acids. Our equipment is suited to analysis conforming to European Pharmacopoeial method 2.2.56, which was adopted in 2014. The test is sensitive to impurities at a threshold of 0.05%, as required by the EP monograph, and capable of determining whether the overall impurity level exceeds the limit of 0.5%.

If you are unsure about what tests are needed, we will consult and advise on the best approach.  We can also discuss topics such as harmonisation or other upcoming Pharmacopoeial changes and how this may affect your business.

Pharmacopoeia Monographs

Our experienced scientists, detailed knowledge of testing and our extensive equipment capabilities means that we are able to offer analysis for the majority of pharmacopoeia monographs including:

• European Pharmacopoeia (EP)
• United States Pharmacopoeia (USP)
• British Pharmacopoeia (BP)
• Chinese Pharmacopoeia (CP)
• Japanese Pharmacopoeia (JP)